Kamada Ltd
NASDAQ:KMDA
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IL |
|
Kamada Ltd
NASDAQ:KMDA
|
531.8m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
409.6B USD |
Loading...
|
|
| US |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
326.4B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
208.3B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
184.3B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
124.4B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83.3B USD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.3B EUR |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
70.2B AUD |
Loading...
|
Market Distribution
| Min | -11 239.1% |
| 30th Percentile | 17.6% |
| Median | 29.8% |
| 70th Percentile | 50.4% |
| Max | 208.2% |
Other Profitability Ratios
Kamada Ltd
Glance View
Kamada Ltd. engages in the development and production of pharmaceutical products. The firm uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Kamada Ltd is 43.8%, which is above its 3-year median of 40.8%.
Over the last 3 years, Kamada Ltd’s Gross Margin has increased from 32.9% to 43.8%. During this period, it reached a low of 32.9% on Sep 30, 2022 and a high of 44.2% on Mar 31, 2025.
